Assembly biosciences reports positive interim results from phase 1b clinical study of long-acting helicase-primase inhibitor candidate abi-5366 showing reductions in viral shedding rate and genital lesion rate in recurrent genital herpes

– 94% reduction in hsv-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of abi-5366 – south san francisco, calif., aug. 08, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim antiviral activity, clinical outcomes, safety and pharmacokinetic (pk) results from a phase 1b study evaluating abi-5366, an investigational long-acting herpes simplex virus (hsv) helicase-primase inhibitor, in participants seropositive for hsv type 2 (hsv-2) with recurrent genital herpes.
ASMB Ratings Summary
ASMB Quant Ranking